First Year of Growth in Past Three Years and Fourth Consecutive Quarterly
Revenue Increase Over Prior Year
SAN DIEGO, Feb. 7 /PRNewswire-FirstCall/ -- CardioDynamics (Nasdaq: CDIC), the innovator and leader of BioZ(R) Impedance Cardiography (ICG) technology, today reported financial results for its fourth quarter and fiscal 2007. Operating results are for the ICG business and do not include results for Vermed which was sold on August 31, 2007.
Key Financial and Operating Results for Fourth Quarter 2007 Compared
with Fourth Quarter 2006
-- Net ICG sales increased 8% to $6.2 million, up from $5.7 million
-- International sales increased 57% to $1.0 million, up from $633,000
-- ICG sensor revenue increased 13% to $1.7 million, or 28% of total
sales, up from $1.5 million
-- ICG monitor sales increased 11% to 174 units, 100 of which were BioZ Dx
systems, 16 BioZ monitors, and 58 Medis ICG monitors, up from 157 ICG
monitors
-- ICG gross profit margin improved slightly to 65%
Key Financial and Operating Results of Fiscal 2007 Compared with Fiscal
2006
-- Net ICG sales increased 10% to $21.9 million, up from $19.8 million
-- ICG sensor revenue increased 8% to $6.7 million, or 31% of total sales,
up from $6.2 million
-- 542 ICG monitors sold, up 9% from 499 monitors
-- Nearly 7,800 ICG monitors and modules sold to date, up 11% from one
year ago
-- ICG gross profit margin was 68%, up from 62%
-- Operating loss was $4.8 million, an improvement of $3.0 million, or 38%
-- Operating cash use of $1.1 million, an improvement of $931,000, or 47%
-- Cash, cash equivalents and short term investments increased
$4.5 million to $8.4, principally as a result of the sale of Vermed
-- Bank debt of $1.7 million was retired during in 2007
Additional Key Operating Milestones for the Fourth Qu
'/>"/>
| SOURCE CardioDynamics Copyright©2008 PR Newswire. All rights reserved |